Nonanticoagulant Actions of Glycosaminoglycans

Prophylaxis and treatment of thromboembolism have made one of the major impacts in medicine. Heparin has widely been used as the most effective drug during the last 50 years. However, its potential side effects have led to the search for equally effective but safer alternatives. At present, the low-molecular-weight heparins are the most promising steps in this direction. Considerable interest has been generated at the same time in exploring other gly cosaminoglycans of the nonheparin type for therapeutic use. The existence of these com pounds has been known for a long time and substantial information has been gathered on glycosaminoglycans such as heparinsulfate, dermatansulfate, and chondroitinsulfate. Many of these substances are derived from animal or plant sources, and some of them have now been synthesized. The aim of the Fourth Symposium on Glycosaminoglycan Research at Villa Vigoni in Loveno at Lake Comolltaly was to summarize the considerable new information in this field. The articles of the present volume are mainly based on a German-Italian collaboration supported by the Vigoni Program. The selected articles describe many different, nonheparin glycosaminoglycans, some of them already in clinical trials as antithrombotic agents. In particular, the interaction of glycosaminoglycans with some cellular elements of blood, especially leukocytes and platelets, are discussed. New methods for their identification and assays are described and considerable emphasis is placed on the pharmacokinetic aspects of these new compounds. Particularly, some nonanticoagulant activities of the glycosamino glycans are discussed in detail."

[1]  D. Gospodarowicz,et al.  Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor , 1987, Journal of cellular physiology.

[2]  J. Harlan.  Leukocyte-endothelial interactions. , 1985, Blood.

[3]  M. W. Peterson,et al.  Cationic neutrophil proteins increase transendothelial albumin movement. , 1987, Journal of applied physiology.

[4]  R. Langer,et al.  Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. , 1983, Science.

[5]  G. Torri,et al.  Synthesis of a N'-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling. , 1994, Analytical biochemistry.

[6]  D. Atha,et al.  Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. , 1986, The Journal of biological chemistry.

[7]  P. Bornstein,et al.  Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[8]  V. Dixit,et al.  Characterization of a cDNA encoding the heparin and collagen binding domains of human thrombospondin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Klagsbrun,et al.  Neutralizing antibodies inhibit the binding of basic fibroblast growth factor to its receptor but not to heparin. , 1989, The Journal of biological chemistry.

[10]  C. Glabe,et al.  Preparation and properties of fluorescent polysaccharides. , 1983, Analytical biochemistry.

[11]  B. Pettmann,et al.  Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Gervasi,et al.  Disposition of a new heparan sulfate with fibrinolytic activity in the rat. , 1993, Arzneimittel-Forschung.

[13]  M. Scully,et al.  Influence of Whole Blood on Standard Curve for Heparin Measurement - Possible Heparin Binding by Red Cells , 1989, Thrombosis and Haemostasis.

[14]  H. Rauvala.  An 18‐kd heparin‐binding protein of developing brain that is distinct from fibroblast growth factors. , 1989, The EMBO journal.

[15]  J. Cassiman,et al.  The core protein of the matrix-associated heparan sulfate proteoglycan binds to fibronectin. , 1990, The Journal of biological chemistry.

[16]  S. Steinberg,et al.  Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Wunder,et al.  Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats. , 1993, The Journal of laboratory and clinical medicine.

[18]  R L Jackson,et al.  Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. , 1991, Physiological reviews.

[19]  R. Lobb,et al.  Clinical applications of heparin‐binding growth factors , 1988, European journal of clinical investigation.

[20]  L. Needham,et al.  Endothelial functional responses and increased vascular permeability induced by polycations. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[21]  P. B. Weisz,et al.  Control of angiogenesis with synthetic heparin substitutes. , 1989, Science.

[22]  R. Dziarski.  Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. , 1989, Journal of immunology.

[23]  C. Discafani,et al.  A quantitative in vivo mouse model used to assay inhibitors of tumor-induced angiogenesis. , 1991, Cancer research.

[24]  D. Rifkin,et al.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation , 1988, The Journal of cell biology.

[25]  Peter J. Polverini,et al.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.

[26]  A. Wellstein,et al.  Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. , 1991, Journal of the National Cancer Institute.

[27]  K. Norrby.  Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. , 1993, Haemostasis.

[28]  H. Rauvala,et al.  The adhesive and neurite-promoting molecule p30: analysis of the amino- terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons , 1988, The Journal of cell biology.

[29]  J. Folkman,et al.  Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. , 1991, Investigative ophthalmology & visual science.

[30]  A. Nagai,et al.  Binding of heparin fractions and other polysulfated polysaccharides to plasma fibronectin: effects of molecular size and degree of sulfation of polysaccharides. , 1985, Biochimica et biophysica acta.

[31]  L. Leung,et al.  Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effects of histidine-rich glycoprotein. , 1989, Blood.

[32]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[33]  R. Tamargo,et al.  Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate , 1990, Journal of Neuro-Oncology.

[34]  C. Parish,et al.  Modification of lymphocyte migration by sulfated polysaccharides , 1986, European journal of immunology.

[35]  K. Preissner,et al.  NEUTRALIZATION OF HEPARIN-LIKE SACCHARIDES BY COMPLEMENT S PROTEIN/VITRONECTIN , 1987, Thrombosis and Haemostasis.

[36]  E. Butcher,et al.  Leukocyte-endothelial cell recognition: evidence of a common molecular mechanism shared by neutrophils, lymphocytes, and other leukocytes. , 1987, Journal of immunology.

[37]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[38]  T. Maciag,et al.  The heparin-binding (fibroblast) growth factor family of proteins. , 1989, Annual review of biochemistry.

[39]  S. Marklund,et al.  Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  I. Macgregor,et al.  Heparin receptors on mouse macrophages. , 1983, Thrombosis research.

[41]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[42]  A. Wunder,et al.  Hepatic uptake of a modified low molecular weight heparin in rats. , 1992, The Journal of clinical investigation.

[43]  R. Carrell,et al.  SERPINS: ANTITHROMBIN AND OTHER INHIBITORS OF COAGULATION AND FIBRINOLYSIS. EVIDENCE FROM AMINO ACID SEQUENCES , 1987, Thrombosis and Haemostasis.

[44]  P. Knowles,et al.  Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. , 1993, Cancer research.

[45]  D. Gospodarowicz,et al.  Fibroblast growth factor , 1986, Molecular and Cellular Endocrinology.

[46]  M. Klagsbrun,et al.  Isolation and characterization of a macrophage-derived heparin-binding growth factor. , 1990, Cell regulation.

[47]  K. Ley,et al.  Fucoidin, but not yeast polyphosphomannan PPME, inhibits leukocyte rolling in venules of the rat mesentery. , 1993, Blood.

[48]  D. Schubert,et al.  Isolation of an adhesion-mediating protein from chick neural retina adherons , 1985, The Journal of cell biology.

[49]  W. T. Morgan,et al.  Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding. , 1987, The Journal of biological chemistry.

[50]  E. Butcher,et al.  Receptors involved in lymphocyte homing: relationship between a carbohydrate-binding receptor and the MEL-14 antigen , 1987, The Journal of cell biology.

[51]  S. Newman,et al.  Structural changes in the NH2-terminal domain of fibronectin upon interaction with heparin. Relationship to matrix-driven translocation. , 1988, The Journal of biological chemistry.

[52]  M. Ruggiero,et al.  Effects of cortisone with and without heparin on angiogenesis induced by prostaglandin e1 and by s180 cells, and on growth of murine transplantable tumours , 1985, International journal of cancer.

[53]  J. Harenberg,et al.  CHARACTERIZATION OF HEPARINS BY HIGH-PERFORMANCE SIZE EXCLUSION LIQUID CHROMATOGRAPHY , 1983 .

[54]  M. Petitou,et al.  Endothelial binding sites for heparin. Specificity and role in heparin neutralization. , 1986, The Biochemical journal.

[55]  G. Conn,et al.  Extracellular matrix heparan sulfate proteoglycans modulate the mitogenic capacity of acidic fibroblast growth factor , 1989, Journal of cellular physiology.

[56]  A. Eldor,et al.  Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. , 1990, Cell regulation.

[57]  S. Rosen,et al.  Possible role for cell-surface carbohydrate-binding molecules in lymphocyte recirculation , 1983, The Journal of cell biology.

[58]  D. Beeler,et al.  Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells , 1984, Journal of cellular physiology.

[59]  N. Ling,et al.  Multiple influences of a heparin-binding growth factor on neuronal development , 1987, The Journal of cell biology.

[60]  D. Rylatt,et al.  Demonstration of lymphocyte surface lectins that recognize sulphated polysaccharides. , 1984, Journal of cell science.

[61]  P. Kaesberg,et al.  Chinese hamster ovary cell adhesion to human platelet thrombospondin is dependent on cell surface heparan sulfate proteoglycan. , 1989, The Journal of clinical investigation.

[62]  J. Wagner,et al.  Sulfated glycosaminoglycans modify growth factor‐induced neurite outgrowth in PC12 cells , 1988, Journal of cellular physiology.

[63]  W. Cowan,et al.  Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[64]  K. Norrby,et al.  Heparin enhances angiogenesis by a systemic mode of action. , 1992, International journal of experimental pathology.

[65]  D. Woolley,et al.  Mast-cell products and heparin stimulate the production of mononuclear-cell factor by cultured human monocyte/macrophages. , 1985, The Biochemical journal.